Interim Report and Half-Year Financial Results

Feb 24th, 2020

Starpharma today released its interim report and financial results for the half-year ended 31 December 2019.

VivaGel BV launched in Asia

Feb 13th, 2020

Starpharma today announced that VivaGel^® BV has been launched in Asia under the brand name BETADINE^TM BV Gel. The product has initially been launched in South East Asia, with further roll-out in additional Asian countries, as regulatory approvals are granted.  

BETADINE^TM BV Gel will be available over-the-counter (OTC), without the need to see a doctor or obtain a prescription. Asia is the third region to launch VivaGel^® BV and represents a large commercial opportunity with access to more than 1.5 billion women.

David McIntyre appointed as non-executive director

Feb 12th, 2020

The Board of Starpharma is pleased to announce the appointment of Mr David McIntyre as an independent non-executive director, effective 1 March 2020.

Starpharma receives US$3M milestone from AstraZeneca

Feb 11th, 2020

Starpharma today announced it has received US$3 million (A$4.5 million) from AstraZeneca following the successful dosing of the first patient in the phase 1 clinical trial of AZD0466 (DEP^® Bcl2/xL conjugate) in December.

Starpharma’s VivaGel® BV regulatory approvals continue in Asia

Sep 3rd, 2019

Read the full news coverage here.

Update on Starpharma’s latest positive interim DEP® trial results, VivaGel® and upcoming milestones

Aug 30th, 2019

To listen to the full interview, click here.

Starpharma sees positive results in ovarian cancer treatment

Aug 29th, 2019

To watch the full news video, click here.

Promising efficacy signals for Starpharma’s DEP® trials

Aug 28th, 2019

To read the full article, click here.

Shareholder Update January 2020

Jan 30th, 2020

In this issue: 

>> VivaGel^® BV launched in the UK

>> AstraZeneca first DEP^® product enters the clinic; triggers US$3M milestone

>> DEP^® cabazitaxel trial moves into phase 2 on positive results

>> Fleurstat BVgel marketing campaign; New Zealand launch planned

>> Dual strategy to achieve approval of the NDA in the US

>> Okamoto joins forces with Japanese government for STI prevention campaign

>> VivaGel^® condom receives regulatory approval in Europe

>> DEP^® docetaxel & DEP^® cabazitaxel clinical trial case studies

>> DEP^® irinotecan phase 1/2 trial

>> New candidate - DEP^® gemcitabine

>> GMP DEP^® facility licence

>> DEP^® combinations add further value

>> Outlook, recent news & events

Shareholder Update July 2019

Jul 1st, 2019

In this issue: 

>> VivaGel^® BV launched in Europe & Australia; US regulatory progress

>> VivaGel condom launched in Japan by Okamoto

>> DEP^® docetaxel & DEP^® cabazitaxel clinical trial update; DEP^® irinotecan trial start & new data

>> Starpharma signs second commercial oncology agreement with AstraZeneca

>> AstraZeneca highlights AZD0466 at 2019 ASCO meeting & upcoming US FDA IND 

>> Patent published for AstraZeneca Bcl2/xL DEP conjugates

>> DEP^® radiotherapeutics

>> Outlook, recent news & events